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Abstract
Background: Respiratory syncytial virus (RSV) affects most infants early in life and 
is associated with increased asthma risk. The specific mechanism remains unknown.
Objective: To investigate the role of uric acid (UA) and IL-1β in RSV immunopathology 
and asthma predisposition.
Methods: Tracheal aspirates from human infants with and without RSV were col-
lected and analyzed for pro-IL-1β mRNA and protein to establish a correlation in 
human disease. Neonatal mouse models of RSV were employed, wherein mice in-
fected at 6-7 days of life were analyzed at 8 days postinfection, 5 weeks postinfec-
tion, or after a chronic cockroach allergen asthma model. A xanthine oxidase inhibitor 
or IL-1 receptor antagonist was administered during RSV infection.
Results: Human tracheal aspirates from RSV-infected infants showed elevated pro-
IL-1β mRNA and protein. Inhibition of UA or IL-1β during neonatal murine RSV infec-
tion decreased mucus production, reduced cellular infiltrates to the lung (especially 
ILC2s), and decreased type 2 immune responses. Inhibition of either UA or IL-1β dur-
ing RSV infection led to chronic reductions in pulmonary immune cell composition 
and reduced type 2 immune responses and reduced similar responses after challenge 
with cockroach antigen.
Conclusions: Inhibiting UA and IL-1β during RSV infection ameliorates RSV immuno-
pathology, reduces the consequences of allergen-induced asthma, and presents new 
therapeutic targets to reduce early-life viral-induced asthma development.
K E Y W O R D S
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1  | INTRODUC TION
Respiratory syncytial virus (RSV) can cause bronchiolitis and af-
fects most infants before age two.1,2 The global health burden 
of RSV includes over three million hospitalizations and ~100 000 
deaths yearly among children under age five.3 Severe RSV with 
bronchiolitis requiring hospitalization in infants is associated with 
an increased risk of childhood asthma.4-6 RSV bronchiolitis involves 
airway epithelial loss, mucus overproduction, pulmonary inflamma-
tory infiltrates, and pulmonary obstruction.7,8 Severe RSV infection 
involves excessive Th2 and Th17 immune responses.9-13 These re-
sponses persist even after viral clearance and are associated with 
enhanced type 2 immune responses in models of asthma induced 
later in life.14 Type 2 innate lymphoid cells (ILC2s) are an impor-
tant source of IL-13, which is associated with mucus production and 
goblet cell hyperplasia in the lung.15-17 RSV induces IL-13-producing 
ILC2 accumulation, which is associated with disease severity.7 IL-1β, 
a regulator of ILC2s,18 has been described to be increased during 
RSV infection and may be directly involved in the pathogenesis.19,20
The precise connections between RSV induction of IL-1β, ILC2 
activation, and RSV immunopathology remain unexplored. Uric acid 
production can induce reactive oxygen species production and thus 
activate the NLRP3 inflammasome, leading to IL-1β liberation.21-23 
Inflammasome-activating metabolic products including uric acid 
(UA) are associated with IL-1β production and subsequent childhood 
wheezing or bronchitis.24 In this work, we investigate the roles of 
UA and IL-1β during neonatal RSV infection using human samples 
and mouse models. We demonstrate that interrupting the uric acid 
pathway using a xanthine oxidase inhibitor (XOI) or blocking the 
downstream inflammation with an IL-1 receptor antagonist (IL-1RA) 
can ameliorate RSV immunopathology. The protective effects of the 
XOI or IL-1RA during RSV persist and are each protective from sub-
sequent cockroach allergen (CRA) induction of asthma exacerbation.
2  | MATERIAL S AND METHODS
2.1 | Animals
The Institutional Animal Care & Use Committee (IACUC), University 
of Michigan, Ann Arbor, approved all animal use protocols, and all ex-
periments proceeded according to IACUC guidelines. BALB/c mice 
6-8 weeks old were purchased from Jackson Laboratory. These were 
bred 1:1 male:female to produce neonates. Each individual litter un-
derwent a single, uniform treatment condition, and the multiple litters 
undergoing different treatment conditions were treated on the same 
dates. Treatment conditions were replicated across multiple mouse co-
horts. Standard pathogen-free conditions were maintained in the Unit 
for Laboratory Animal Medicine at the University of Michigan.
2.2 | Patient samples
All human studies were performed in accordance with an approved 
University of Michigan Institutional Review Board protocol. Tracheal 
aspirate samples were obtained from RSV-infected infants hospital-
ized and mechanically ventilated in a pediatric intensive care unit; 
baseline clinical characteristics were collected from the medical 
G R A P H I C A L  A B S T R A C T
Neonatal RSV infection is associated with increases in pulmonary uric acid and IL-1β and lung immunopathology. XOI or IL-1RA 
administration during neonatal RSV infection leads to reduced RSV immunopathology. XOI or IL-1RA administration during neonatal RSV 
infection leads to reduced type 2 immune responses during a subsequent model of asthma.
Abbreviations: IL-1RA, IL-1 receptor antagonist; RSV: Respiratory syncytial virus; XOI, xanthine oxidase inhibitor.
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record and are summarized in Table S1. Infants' parents or legal guard-
ians provided informed consent. The samples were directly aspirated 
from the endotracheal tube. RSV infection was detected by clinical 
sputum PCR for initial diagnosis; this was confirmed subsequently by 
PCR in the laboratory (see below). Infants intubated for other non-
infectious reasons provided control samples. Samples were divided 
for protein and cDNA analysis. Protein samples were diluted 1:1 with 
PBS-containing complete anti-protease cocktail (Sigma-Aldrich) and 
0.5% Triton X-100 nonionic detergent to dissociate mucus. TRIzol 
reagent was used for RNA extraction (Invitrogen). cDNA was syn-
thesized using a murine leukemia virus reverse transcriptase (Applied 
Biosystems). Pro-IL-1β mRNA was analyzed via commercial TaqMan 
primers (Thermo Fisher Scientific). IL-1β and CCL5 protein were 
measured using a Bio-Plex 200 System (Bio-Rad Laboratories).
2.3 | RSV
RSV line 19, subgroup A, isolated from an infected infant at the 
University of Michigan Children's Hospital, was used for all experi-
ments as previously described.25 We have previously demonstrated 
animal models with this virus mimic human RSV with mucus hyperse-
cretion and cytokine dysregulation.26 Neonatal animals were infected 
with 1.8 × 105 plaque-forming units (PFU) via intranasal instillation.
2.4 | Primary RSV infection time course
Neonatal BALB/c mice were infected with RSV at 6-7 days old. Mice 
were sacrificed at days 2, 4, 6, 8, and 14 postinfection. Control mice 
were sham-infected with carrier fluid. Separate age-matched control 
groups were used at each time point. Lungs were flash-frozen for 
RNA evaluation. BAL was collected as below.
2.5 | Primary RSV infection
BALB/c mice were infected with RSV at 6-7 days old. Mice were 
treated daily with the relevant inhibitor starting on the day of infec-
tion for 7 days. At 4, 6, or 8 days postinfection, the mice were killed. 
Whole lungs and lung draining lymph nodes (LDLN) were isolated for 
flow cytometry, histology, PCR, and/or cytokine analysis (Figure S1). 
Control RSV-infected animals were treated with carrier fluid in these 
experiments. For experiments where the XOI and IL-1RA groups 
were both included, the IP carrier was fluid-treated, and the RSV-
infected control group was used.
2.6 | Xanthine oxidase inhibitor treatment
The XOI, allopurinol, (Sigma-Aldrich) was administered at 25 μg 
per mouse (approximately 10 mg/kg) via intraperitoneal injection 
(volume 50 µL) daily starting on the day of RSV infection for seven 
doses. The dose was chosen based on prior dose-finding experi-
ments (internal data) and known human dosing for allopurinol in 
children.27-29
2.7 | Interleukin-1 receptor antagonist
The IL-1RA (Cayman Chemical) was administered daily at 0.2 μg per 
mouse (approximately 0.08 mg/kg) via intranasal instillation (volume 
5 µL) starting on the day of RSV infection for seven doses. This dose 
was chosen based on prior dose-finding experiments that suggested 
this dose was safe and potentially effective.
2.8 | Chronic RSV model
BALB/c mice were infected with RSV at days 6-7 of life. The mice 
were treated daily with either XOI or IL-1RA as above. After seven 
daily treatments, the mice rested 4 weeks. RSV-infected controls 
were treated with carrier fluid. The mice were euthanized, and whole 
lungs and LDLN were isolated for flow cytometry, histology, PCR, 
and/or cytokine analysis (Figure S1A).
2.9 | Cockroach antigen (CRA) model
BALB/c mice were infected with RSV as above at 6-7 days old. 
The mice were treated daily with either inhibitor as above. After 
seven treatments, the mice rested four additional weeks. The 
mice then began CRA sensitization and challenge as previously de-
scribed.14,30,31 Briefly, mice were sensitized with 500 protein nitro-
gen units (PNU) of CRA on days 0, 1, and 2 and challenged with 500 
PNU on days 14, 20, 22, and 23. Clinical-grade CRA (as used in skin 
testing) was used for these experiments. On day 24, the mice were 
killed, and whole lungs and LDLN were isolated for flow cytometry, 
histology, PCR, and/or cytokine analysis (Figure S1B).
2.10 | Flow cytometry
Lungs were enzymatically dispersed with 1 mg/mL collagenase A (Roche) 
and 20 U/mL DNase I (Sigma) in RPMI with 10% FCS and further dispersed 
via 18-gauge needle (10-mL syringe). RBCs were lysed and samples filtered 
through 100-micron nylon mesh. Cells were re-suspended in PBS. LIVE/
DEAD Stain Kit identified live cells (Thermo Fisher Scientific). Cells were 
washed and re-suspended in PBS with 1% FCS. Fc receptors were blocked 
with anti-CD16/32 (BioLegend). Surface markers were identified using 
the following clonal antibodies, all from BioLegend: anti-Gr-1 (RB6-8C5), 
B220 (RA3-6B2), CD3 (145-2C11), Ter119 (Ter-119), CD11b (M1/70), 
CD25 (PC61), CD45 (30-F11), ST2 (DIH9), c-Kit (2B8), CD90 (53-2.1), 
CD4 (RM4-5), CD3 (17A2), CD8 (53-5.8), CD69 (H1.2F3), CD11c (N418), 
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MHCII (M5/114.15.2), and CD103 (2E7). SiglecF was from BD Biosciences. 
For innate lymphoid staining, anti-CD3, CD11b, B220, Gr-1, TER119, and 
GATA3 were used (eBioscience/Thermo Fisher) in accordance with a 
previously published protocol.32 For ILC2: Lin-(CD3, CD11b, B220, GR-1, 
TER119) CD45+ CD25+CD90+ ST2+c-Kit+ +GATA3+. For eosinophils: 
SSChighCD11b+ SiglecF+. For neutrophils: SSChighCD11b+ SiglecF-GR-1+. 
For conventional DC: CD11b+ CD11c+MHCII+, CD103-. For DC 103+: 
CD11c+ CD11b- MHCII+ CD103+. For interstitial macrophages: CD11b+ 
CD11c-F4/80+. For CD4+ T cells: CD3+CD4+, and CD8+ T cells: CD3+ 
CD8+. Data were collected using a NovoCyte Flow Cytometer (ACEA 
Bioscience), and analysis utilized FlowJo software (Tree Star, OR). Gating 
strategies are available in the Supplementary Data (Figure S4).
2.11 | Histology
The middle and inferior lobes of the right lung were perfused with 
formaldehyde and embedded in paraffin. Five-micron lung sections 
were stained with periodic acid-Schiff (PAS) or hematoxylin/eosin 
(H/E). A Zeiss Axio Imager Z1 with AxioVision 4.8 software (Zeiss, 
Munich, Germany) collected photomicrographs.
2.12 | Mucus scoring analysis
Slides from PAS-stained lungs were coded and scored by a blinded 
observer. Mucus was quantified on a score of 1-4, with 1 = minimal/
no mucus; 2 = slight: multiple airways with goblet cell hyperplasia 
and mucus; 3 = moderate: multiple airways with significant mucus 
and some plugging; and 4 = severe: significant mucus plugging.14
2.13 | Quantitative RT-PCR
TRIzol reagent was used for lung tissue homogenization and RNA 
extraction (Invitrogen). cDNA was synthesized using murine leu-
kemia virus reverse transcriptase (Applied Biosystems) incubated 
at 37°C followed by 95°C to stop the reaction. Real-time quantita-
tive PCR (qPCR) using TaqMan (Thermo Fisher Scientific) primers 
with a FAM-conjugated probe measured pro-IL-1β (Mm00434228 
and Hs01555410), IL-4 (Mm00445259), IL-5 (Mm00439646), 
IL-13 (Mm00434204), CCL5 (Mm01302428), xanthine oxidase 
(Mm00442110), interferon-γ (Mm00801778), and 18S (Hs99999901 
and Mm03928990). A previously described primer system was used 
to measure Gob5.33 Custom primers were used for RSV-G (forward: 
CCA AGC AAA CCC AAT AAT GAT TT; reverse: GCC CAG CAG GTT 
GGA TTG T) (Sigma-Aldrich). Gene expression was normalized to 
18S expression with fold change values calculated using 2−ΔΔ cycle 
threshold method relative to uninfected wild-type controls. For the 
human pro-IL-1β expression, human 18S expression was used for 
normalization. A 7500 Real-Time PCR System (Applied Biosystems) 
was used.
2.14 | Re-stimulation of lung-draining lymph node 
(LDLN) cells with RSV or CRA
LDLN were digested via 1 mg/mL collagenase A (Roche) and 25 U/
mL DNase I (Sigma-Aldrich) in RPMI with 10% FCS for 45-60 min-
utes at 37°C and further dispersed via 18-gauge needle (10-mL sy-
ringe). RBCs were lysed and samples filtered through 100-micron 
nylon mesh. Single-cell suspensions of lymph nodes at a concentra-
tion of 2.5 × 106 cells/mL (0.2 mL plated per well) in a 96-well plate 
were re-stimulated with RSV 5 × 105 PFU or CRA 300 PNU as appro-
priate. The supernatants were collected at 48 hours and analyzed for 
the following cytokines: IFN-γ, IL-4, IL-5, and IL-13 using a Bio-Plex 
bead-based cytokine assay (Bio-Rad Laboratories).
2.15 | Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed on neonatal mice after 
euthanasia. The trachea and lungs in the neck and chest were di-
rectly exposed. A 26-gauge needle was inserted into the trachea, 
200 μL of PBS was instilled gently, and the lungs were directly visual-
ized to inflate. Approximately 100 μL was returned upon application 
of suction. This was frozen at −20°C until analysis.
2.16 | Lung extracts
The left lung was taken for protein measurement. Each lung was 
placed in 1 mL Tissue Protein Extraction Reagent (Thermo Fisher), 
and total protein was extracted according to the manufacturer's pro-
tocol. This was frozen at −20°C until analysis.
2.17 | Uric acid measurements
BAL samples taken from neonatal mice at 6 days postinfection after 
euthanasia were analyzed for uric acid content. The Uric Acid Assay Kit 
(Cayman Chemicals) using the manufacturer's instructions was used.
2.18 | Enzyme-linked immunosorbent assays
Murine IL-1β protein was quantified from lung extract samples taken 
from naïve or infected mice at 6 days postinfection after euthanasia. 
We used the R&D DuoSet ELISA Kit (R&D Systems) and followed the 
manufacturer's instruction.
2.19 | Statistical analysis
Prism 7 (GraphPad Software) was used for data analysis. Data are pre-
sented as mean values ± SEM. Unpaired, two-tailed t test was used to 
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compare data with two groups. ANOVA was used to compare three or 
more groups. A P-value < .05 was considered statistically significant.
3  | RESULTS
3.1 | RSV induces pulmonary IL-1β expression in 
infants and neonatal mice
In this work, we initially analyzed tracheal aspirates from human 
infants with severe RSV for the presence of IL-1β. We detected 
significantly increased mRNA expression of pro-IL-1β and protein 
production of IL-1β in the samples of RSV+ infants compared with 
controls (Figure 1A,B). Protein production of CCL5, a chemokine 
known to be correlated with severe RSV disease,34 was also signifi-
cantly elevated in samples from RSV-infected infants (Figure 1C). 
IL-1β is known to be a potent cytokine that amplifies the immune 
response through the activation of cytokine cascades as well as 
activation of critical innate immune cells, such as ILC2s.18,19,35,36 
Therefore, we decided to investigate the impact of IL-1β-
induced immune activation on type 2 immunity-associated RSV 
immunopathology.
F I G U R E  1   RSV induces pulmonary IL-1β expression in humans and mice neonates. (A) cDNA from tracheal aspirates from human infants 
with RSV and from control patients intubated for noninfectious reasons underwent qPCR to determine pro-IL-1β mRNA (N ≥ 9). (B) Tracheal 
aspirates from human infants underwent Bio-Plex to determine IL-1β protein concentration (N ≥ 6). (C) Tracheal aspirates from human infants 
were measured via Bio-Plex to determine CCL5 protein concentration (N ≥ 7). (D) Mice infected with RSV were killed at 2, 4, 8, and 14 days 
postinfection (dpi) and compared with age-matched controls. Lungs were homogenized and mRNA extracted to determine CCL5, pro-IL-1β, 
and xanthine oxidase mRNA expression (N ≥ 5). (E) BAL fluid from mice with RSV and age-matched controls was taken 8 days postinfection 
and assayed for uric acid (N ≥ 6). Data represent mean ± SEM. *P < .05, **P < .01
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F I G U R E  2   Administration of the XOI or IL-1RA ameliorates RSV infection. Mice were infected with RSV and treated with the XOI 
or IL-1RA and compared with infected mice at 6 or 8 days postinfection. (A) Lungs were embedded in paraffin and periodic acid-Schiff 
(PAS)-stained to visualize mucous (pink/purple staining) or hematoxylin/eosin (H/E)-stained to evaluate inflammatory cell infiltrates. 
Representative photographs are shown (N ≥ 5). (B) Mucus scoring was performed on blinded histological slides on a scale of 1-4 for mucus 
production (N ≥ 4). (C) Lungs were homogenized and mRNA extracted to determine Gob5 mRNA expression (N ≥ 5) and CCL5 mRNA 
expression (N ≥ 6). (D) BAL fluid at 6 days postinfection was collected as described and assayed for uric acid content (N ≥ 4). Data represent 
mean ± SEM. *P < .05. **P < .01, ***P < .001
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F I G U R E  3   Administration of the XOI or IL-1RA reduces pulmonary immune infiltrates and lymphocyte responsiveness with RSV 
infection. Mice were infected with RSV and treated with the XOI or IL-1RA and compared with infected mice at 8 days postinfection. (A 
and B) Lungs were processed into single-cell suspension, then stained and analyzed via flow cytometry for type 2 innate lymphoid cells 
(N ≥ 6) and neutrophils (N ≥ 5). (C, D, E, and F) Lung draining lymph nodes were processed into single-cell suspension and re-stimulated with 
RSV in vitro for 48 h to determine cytokine protein levels in the supernatant including IL-4, IL-5, IL-13, and IFN-γ (N ≥ 3). Data represent 
mean ± SEM. *P < .05, **P < .01, ***P < .001, ****P < .0001
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To study the role of IL-1β during RSV infection, a neonatal murine 
model was utilized to recapitulate responses in clinical disease in in-
fants (Figure S1A).14,37 To compare this model to the above human 
samples, neonatal BALB/c mice were infected with RSV line 19 and 
we measured mRNA expression of pro-IL-1β and CCL5 in the lung. 
We observed significant increases in mRNA expression of both cy-
tokines (Figure 1D), resembling the RSV infection in infants. Various 
metabolic mediators have been identified to drive IL-1 pathway ac-
tivation,23,36 and RSV has been shown to alter metabolic profiles 
in mice as a key step driving immunopathology.38 Examination of a 
key metabolic activator of IL-1β, uric acid (UA), was performed by 
analyzing the expression of xanthine oxidase that converts xanthine 
to UA. A time course of xanthine oxidase (XO) in the lungs of neo-
natal mice revealed high expression that peaked at 4 days postin-
fection (dpi) (Figure 1D). RSV infection was confirmed in the model 
via PCR, with RSV-G peaking on day 4 postinfection (Figure S1C). 
Bronchoalveolar lavage (BAL) fluid taken from neonatal mice at 
8 days postinfection demonstrated elevated levels of UA in RSV-
infected mice compared to controls (Figure 1E). Thus, we observed 
contemporaneous increased expression of XO, increased produc-
tion of UA, and increased production of pro-IL-1β during neonatal 
RSV infection.
3.2 | Inhibition of uric acid or IL-1β pathway 
ameliorates RSV immunopathology
To examine the role of the XOI or IL-1RA on RSV immunopathology, 
neonatal BALB/c mice infected with RSV were treated daily with either 
the xanthine oxidase inhibitor (XOI) or interleukin 1 receptor antagonist 
(IL-1RA) (Figure S1A). Examination of the histopathology demonstrated 
that the XOI treatment in particular reduced mucus production and gob-
let cell metaplasia compared with infected controls as well as an overall 
decrease in cellular infiltrates in the treated groups (Figure 2A,B). We 
also observed downregulation of the mucous-associated gene Gob5 
and the chemokine CCL5 in both treated groups (Figure 2C). We evalu-
ated viral clearance rates associated with the treatments using RSV-G 
RNA expression. No difference between control mice and XOI-treated 
mice was observed at day 4 of infection (Figure S1D). However, uric 
acid levels in BAL at day 6 postinfection were lower in XOI-treated ani-
mals compared to control mice (Figure 2D). Local lung IL-1β levels were 
not significantly changed in XOI- or IL-1RA-treated animals at 4 days 
postinfection (dpi) (Figure S1E). These data suggest that UA and IL-1β 
have important roles during RSV pathogenesis.
To characterize the immune response in neonatal mice infected 
with RSV that were treated with either XOI or IL-1RA, we analyzed 
pulmonary leukocyte populations by flow cytometry. During RSV 
infection, increased numbers of activated ILC2s have been re-
ported.39 In the present studies, ILC2 (Figure 3A) and neutrophils 
(Figure 3B) were significantly increased in RSV infection and re-
duced in both XOI- or IL-1RA-treated mice compared with infected 
controls. Other leukocytes including macrophages, CD4+ T cells, 
eosinophils, and dendritic cell populations were not significantly 
altered by RSV infection at this time point (Figure S1F,G,H,I,J). To 
further evaluate the immune response, we measured cytokine lev-
els from isolated lung draining lymph node (LDLN) cells after in vitro 
re-stimulation with RSV and observed that the XOI-treated neona-
tal group had reduced IL-4, IL-5, and IL-13 production (Figure 3C-E) 
and increased IFN-γ and IL-17A production (Figure 3F, Figure S3A) 
compared to RSV-infected control animals. The IL-1RA-treated 
group also demonstrated reduced IL-4 production (Figure 3C), but 
no change in IL-5 or IL-13 (Figure 3D,E), and an increase in IFN-γ and 
IL-17A levels compared to the control group (Figure 3F, Figure S3A). 
Altogether, both XOI and IL-1RA treatment reduce type 2 immune 
responses during RSV infection and promote a type 1 immune 
response.
3.3 | Control of RSV disease severity by XOI or IL-1RA 
treatments establishes long-lasting immune changes
To evaluate long-term consequences of XOI or IL-1RA treatment 
during RSV infection, neonatal mice were infected at days 6-7 of life 
and treated with the XOI or IL-1RA daily for 7 days. At 5 weeks after 
infection, the lungs were evaluated for their mucus expression and 
immune phenotype. No significant differences were observed be-
tween naïve animals, RSV-infected mice, or either treated group in 
visible lung pathology by PAS staining or in mucus gene expression 
by qPCR (Figure S2A,B,C). However, there was a persistent increase 
in ILC2s in the lungs of RSV-infected mice, which was significantly 
reduced in the groups of mice that were treated with XOI or IL-1RA 
(Figure 4A). In addition, increased macrophage, CD103+ dendritic 
cell, and eosinophil numbers seen in the RSV group were decreased 
in the IL-1RA-treated group, while only a nonsignificant trend toward 
reduction in these cell types was observed in the XOI-treated group 
(Figure 4B-D). CD4+ T cell and neutrophil numbers were unchanged 
in the treated groups (Figure S2D). To evaluate the lymphocyte re-
sponses to RSV re-stimulation, LDLN were harvested from animals 
infected with RSV with XOI or IL-1RA treatment and compared to 
infected controls. The XOI-treated mice showed an increase in IL-4 
production (Figure 4E), no change in IL-5 (Figure 4F), and a significant 
decrease in IL-13 production (Figure 4G) compared to RSV-infected 
mice. The IL-1RA-treated group showed significant reduced produc-
tion of IL-4, IL-5, and IL-13 (Figure 4E-G). Both treated groups showed 
a decrease in IFN-γ and no change in IL-17A production (Figure 4H, 
Figure S3B). Thus, there appear to be persistent innate immune cells 
in the lung and altered immune responses long after RSV infection 
has cleared that are attenuated in the XOI- or IL-RA-treated animals.
3.4 | Control of RSV infection severity by 
XOI or IL-1RA treatments ameliorates exacerbated 
development of asthma
In order to evaluate whether the changes with XOI or IL-1RA treatment 
during RSV infection would affect subsequent asthma development, 
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F I G U R E  4   Administration of the XOI or IL-1RA during RSV infection leads to durable immune changes. Mice were infected with RSV 
and treated with the XOI or IL-1RA and compared with infected mice at 5 wk postinfection. (A, B, C, D) Lungs were processed into single-
cell suspensions, then stained and analyzed via flow cytometry for type 2 innate lymphoid cells, macrophages, CD103+ dendritic cells, and 
eosinophils (N ≥ 4). (E, F, G, and H) Lung draining lymph nodes were processed into single-cell suspension and re-stimulated with RSV in vitro 
for 48 h to determine cytokine protein levels in the supernatant including IL-4, IL-5, IL-13, and IFN-γ (N ≥ 6). Data represent mean ± SEM. 
*P < .05, **P < .01, ***P < .001, ****P < .0001
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RSV-infected mice were exposed to an allergen challenge model of 
asthma. Five-week-old mice previously infected with RSV and treated 
with XOI or IL-1RA were sensitized and challenged with cockroach 
antigen (CRA) (Figure S1B). Lung histology demonstrated a decrease 
in mucus deposition (Figure 5A) and less prominent inflammatory 
leukocyte infiltrates in the group of mice treated with XOI or IL-1RA 
compared to untreated animals during the neonatal RSV infection 
(Figure 5B). Mucus scoring was lower in the treated animal groups as 
well (Figure 5C). Gob5 mucus-related gene expression in the lung was 
reduced in XOI- and IL-1RA-treated animals (Figure 5D). CRA treat-
ment increased IL-13 gene expression in the lung, and the enhanced 
IL-13 was decreased in the IL-1RA-treated group (Figure 5E).
To investigate the effect of blocking the XO and IL-1β path-
ways during RSV infection on the lung immune environment, flow 
cytometry was performed in the asthma model. Interestingly, 
the XOI- or IL-1RA-treated mice demonstrated no change in ILC2 
numbers during CRA challenge when compared to RSV-infected/
CRA-treated controls (RSV/CRA) (Figure 6A). However, reduced 
numbers of interstitial macrophages in the lung of the XOI- or IL-
1RA-treated mice were observed (Figure 6B). Although there were 
no significant differences in the CD4+ T cells or CD103+ den-
dritic cells in either of the treated groups (Figure 6C,F), there was 
a significant reduction in eosinophils and CD11b+ dendritic cells 
in IL-1RA-treated mice (Figure 6D,E). Thus, differences in the cel-
lular infiltrate changes in the XOI- or IL-1RA-treated groups lead 
to reductions in pulmonary immune infiltrates during subsequent 
induction of asthmatic disease.
Finally, we evaluated the acquired immune response by in vitro 
re-stimulation of LDLN from asthmatic mice with allergen. The 
groups treated with XOI and IL-1RA during neonatal RSV infection 
both demonstrated reduced IL-4, IL-5, and IL-13 production upon 
CRA re-stimulation (Figure 6G-I), with no change in IL-17A produc-
tion (Figure S3C), and the IL-1RA group also showed reduced IFN-γ 
(Figure 6J). These data suggest that type 2 immunity induced in the 
RSV/CRA model is reduced by XOI or IL-1RA treatment during neo-
natal RSV infection. Together, these data indicate that control of 
neonatal RSV immunopathology, by XOI or IL-1RA treatment, trans-
lates into long-term control of type 2 immune responses in the lung 
upon later allergen sensitization and attenuates the RSV-associated 
asthma predisposition.
4  | DISCUSSION
In this work, we demonstrated that inhibition of the uric acid 
or IL-1β pathways by the XOI (allopurinol) or IL-1RA (Anakinra) 
treatments in RSV-infected neonatal mice decreased RSV immu-
nopathology and ameliorated the long-term type 2 immunity-as-
sociated asthma induction. Given the high global health burden of 
RSV, with over three million hospitalizations and ~100 000 deaths 
worldwide yearly among children under age five, disrupting the 
immunopathology of early-life RSV infection with allopurinol or 
Anakinra could directly have a significant impact on health. In 
addition, because early-life viral infections, especially RSV, are 
associated with development of asthma, these treatments might 
lead to long-term reductions in childhood asthma. Prior work has 
shown the important role of metabolic alterations in RSV immu-
nopathology.38 Thus, these studies provide novel and striking evi-
dence that interrupting this metabolic and inflammatory process 
could have significant clinical impact.
Uric acid is a product of purine metabolism produced by xanthine 
oxidase40 and is produced during cell injury with viral infections.41 
UA has been implicated in house dust mite pulmonary injury and as 
an adjuvant promoting asthma; allopurinol can disrupt UA's delete-
rious effects.40,42-44 Allopurinol is well-studied with a long-standing 
safety record45 and has been used for many years in diseases such 
as gout to normalize the level of system UA to reduce flares.46,47 In 
addition, dosing and safety data are available in children, particularly 
with treating tumor lysis syndrome.27-29 This process of blocking UA 
production may be especially viable in disease such as viral infec-
tions that promote high levels of production since humans do not 
produce uricase to further process UA.48 Thus, while further clinical 
research will be needed, safety and dosing have already been estab-
lished in children and infants making this a potential clinical option to 
add to the clinical "toolbox."
IL-1β is a major inflammasome output, which can be activated by 
UA through the NLRP3 pathway.23,36 IL-1β is elevated in nasopharyn-
geal aspirates of infants with RSV and in murine models plays a role 
in RSV immunopathology,19,49,50 and a role for NLRP3-inflammasome 
activation of IL-1β has been shown in models of rhinovirus.51 IL-1β 
promotes type 2 immune responses in asthma, IL-1β is upregulated in 
BAL fluid from Th2/Th17-polarized asthmatic patients, IL-1β elevation 
is associated with increased rates of hospitalization in asthmatic pa-
tients, and murine asthma models demonstrate a role for IL-1β in regu-
lating barrier function and mucin production.20,52-54 While we suspect 
that the IL-1RA affects IL-1β signaling through the IL-1 receptor, we 
acknowledge that these data do not definitively prove this connec-
tion; future studies are needed to understand this mechanism fully.
Like allopurinol, there are established safety and dosing pro-
files for IL-1RAs in children.55-57 IL-1RAs, particularly Anakinra, 
are widely used in juvenile rheumatoid arthritis to reduce IL-1-
related inflammation.55-57 Furthermore, IL-1RAs are effectively 
and safely deployed in various autoinflammatory syndromes, in-
cluding cryopyrin-associated periodic fever syndromes, tumor 
necrosis factor-associated periodic fever syndromes, familial 
Mediterranean fever, and adult-onset Still's disease.58-61 However, 
IL-1RAs have not been evaluated as a therapy for RSV to poten-
tially reduce asthma.
There are differences in the outcome of disease phenotypes 
between the XOI and IL-1RA treatments in this study. These 
differences are likely because UA can affect multiple pathways 
including inflammasome activation, while IL-1β may have a more 
targeted and specific effect on the downstream inflammation. In 
this case, the lack of decrease in IL-1β during RSV infection with 
XOI treatment suggests IL-1 independent pathways may play a 
role. Allopurinol appears to provide a more robust reduction in 
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F I G U R E  5   Administration of the XOI or IL-1 receptor antagonist during RSV infection ameliorates lung immunopathology during 
subsequent cockroach antigen sensitization. Mice were infected with RSV and treated with the XOI or IL-1RA. Five weeks after the start of 
infection, mice underwent CRA sensitization and challenge. Control mice were uninfected, CRA-treated mice (CRA only), and RSV-infected/
CRA-treated mice (RSV/CRA). (A and B) Lungs were embedded in paraffin and periodic acid-Schiff (PAS)-stained to visualize mucous 
(pink/purple staining) or hematoxylin/eosin (H/E)-stained to evaluate inflammatory cell infiltrates. Representative photographs are shown 
(N ≥ 9). (C) Mucus scoring was performed on blinded histological slides on a scale of 1-4 for mucus production (N ≥ 9). (D and E) Lungs were 
homogenized and mRNA extracted to determine Gob5 (N ≥ 8) and IL-13 mRNA expression (N ≥ 3). Data represent mean ± SEM. *P < .05, 
**P < .01
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RSV immunopathology acutely than the IL-1RA, whereas the IL-
1RA effects are more persistent when examining pulmonary in-
filtrates and LDLN at later time points, despite the slightly higher 
viral levels seen in the acute infection. Further, CD103+ dendritic 
cells were reduced in the IL-1RA-treated mice in the later aller-
gen model in the IL-1RA treatment, which corresponded with a 
reduction in IFN-γ on LDLN re-stimulation consistent with prior 
work.62,63 Both inhibitors lead to marked reductions in ILC2s, 
F I G U R E  6   Administration of the XOI or IL-1 receptor antagonist during RSV infection ameliorates type 2 immune responses during 
subsequent cockroach antigen sensitization. Mice were infected with RSV and treated with the XOI or IL-1RA. Five weeks after the start of 
infection, mice underwent CRA sensitization and challenge. Control mice were uninfected, CRA-treated mice (CRA only) as well as RSV-
infected/CRA-treated mice (RSV/CRA). (A, B, C, D, E, F) Lungs were processed into single-cell suspensions, then stained and analyzed via 
flow cytometry for type 2 innate lymphoid cells (N ≥ 7), macrophages (N ≥ 8), CD4+ T cells (N ≥ 4), eosinophils (N ≥ 8), CD11b+ dendritic 
cells (N ≥ 8), and CD103+ dendritic cells (N ≥ 8). (G, H, I, and J) Lung draining lymph nodes were processed into single-cell suspension and 
re-stimulated with RSV in vitro for 48 h to determine cytokine protein levels in the supernatant including IL-4, IL-5, IL-13, and IFN-γ (N ≥ 8). 
Data represent mean ± SEM. *P < .05, **P < .01, ***P < .001, ****P < .0001
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which can play a role in RSV immunopathology and type 2 im-
mune responses.39 Given the perceived ability of ILC2s to estab-
lish an allergic immune environment in the lung,64 this modified 
phenotype may be desirable and play a key role. The differences 
extend to the later development of allergic disease, where the 
IL-1RA-treated mice demonstrate greater reductions in pulmo-
nary IL-13 expression, pulmonary cellular infiltrates, and type 2 
immune responses in LDLN lymphocytes than XOI-treated ani-
mals. However, since both treatments reduce the overall disease, 
the use of them individually or together may be a clinical decision 
based upon the viral-induced phenotype and severity presented 
in each infant. These differences may depend upon, for example, 
the level of UA vs IL-1β in airway samples or the metabolic state 
of the infected patient.
This novel work verifies and connects the metabolic conse-
quences and immunopathology of RSV infection. We propose a 
conceptual model (see graphical abstract) to explain how these two 
processes might be linked. We show that UA production is induced 
by RSV infection and that this activates the inflammasome, leading 
to IL-1β production. IL-1β, known to induce ILC2 activation and pro-
liferation, likely promotes a type 2 immune environment coupled 
with persistent changes in the airway, such as goblet cell metapla-
sia. By inhibiting either xanthine oxidase or the IL-1 receptor, we 
can interrupt this process, with beneficial immediate and long-term 
consequences. This neonatal murine model reflects the time in life 
that this infection has the most consequences in humans.2 However, 
since the clinical burden of RSV is not limited to infants, these treat-
ments could have impacts on RSV infection in the elderly as well as 
those with chronic lung disease, such as COPD.65-67 This work ex-
tends to development of asthma early in life, which may be a clinical 
consequence of RSV infection, and these inhibitors may attenuate 
subsequent asthma. Further research, preclinical and clinical, could 
provide better definitions of how and when to use specific inhibitors 
during disease.
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